Tower Research Capital (TRC)’s ARS Pharmaceuticals SPRY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $110K | Buy |
6,284
+158
| +3% | +$2.76K | ﹤0.01% | 2306 |
|
|
2025
Q1 | $77.1K | Sell |
6,126
-39,450
| -87% | -$496K | ﹤0.01% | 1921 |
|
|
2024
Q4 | $481K | Buy |
45,576
+41,269
| +958% | +$435K | 0.01% | 1089 |
|
|
2024
Q3 | $62.5K | Sell |
4,307
-3,383
| -44% | -$49.1K | ﹤0.01% | 2594 |
|
|
2024
Q2 | $65.4K | Buy |
7,690
+7,459
| +3,229% | +$63.5K | ﹤0.01% | 2885 |
|
|
2024
Q1 | $2.36K | Sell |
231
-6,834
| -97% | -$69.8K | ﹤0.01% | 5060 |
|
|
2023
Q4 | $38.7K | Sell |
7,065
-28,581
| -80% | -$157K | ﹤0.01% | 3288 |
|
|
2023
Q3 | $135K | Buy |
35,646
+26,143
| +275% | +$98.8K | ﹤0.01% | 1743 |
|
|
2023
Q2 | $63.7K | Sell |
9,503
-198
| -2% | -$1.33K | ﹤0.01% | 2365 |
|
|
2023
Q1 | $64K | Buy |
9,701
+1,539
| +19% | +$10.2K | ﹤0.01% | 2284 |
|
|
2022
Q4 | $70K | Buy |
8,162
+1,542
| +23% | +$13.2K | ﹤0.01% | 2110 |
|
|
2022
Q3 | $35K | Sell |
6,620
-3,939
| -37% | -$20.8K | ﹤0.01% | 3475 |
|
|
2022
Q2 | $45K | Sell |
10,559
-9,244
| -47% | -$39.4K | ﹤0.01% | 2993 |
|
|
2022
Q1 | $70K | Buy |
19,803
+17,009
| +609% | +$60.1K | ﹤0.01% | 2462 |
|
|
2021
Q4 | $19K | Sell |
2,794
-1,780
| -39% | -$12.1K | ﹤0.01% | 3742 |
|
|
2021
Q3 | $46K | Buy |
4,574
+3,478
| +317% | +$35K | ﹤0.01% | 3035 |
|
|
2021
Q2 | $34K | Buy |
1,096
+439
| +67% | +$13.6K | ﹤0.01% | 3360 |
|
|
2021
Q1 | $29K | Buy |
+657
| New | +$29K | ﹤0.01% | 3589 |
|